Bispecific antibody drug conjugate - BrickBio
Latest Information Update: 16 Jun 2023
At a glance
- Originator BrickBio; Undisclosed Company
- Class Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Preclinical trials in Solid tumours in USA (Parenteral) before April 2023
- 14 Apr 2023 Pharmacodynamics and pharmacokinetics data from a preclinical studies in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 06 Jan 2021 BrickBio and an undisclosed company agree to co-develop antibody drug conjugate